ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 524.86B
Enterprise Value 325.65B
Trailing P/E 18.78
Forward P/E 110.10
PEG Ratio (5 yr expected) 10.65
Price/Sales (ttm)5.52
Price/Book (mrq)2.45
Enterprise Value/Revenue 35.70
Enterprise Value/EBITDA 611.32

Trading Information

Stock Price History

Beta (3Y Monthly) 1.70
52-Week Change 3-6.14%
S&P500 52-Week Change 3-0.33%
52 Week High 3141.86
52 Week Low 392.56
50-Day Moving Average 3118.65
200-Day Moving Average 3126.58

Share Statistics

Avg Vol (3 month) 31.76M
Avg Vol (10 day) 31.65M
Shares Outstanding 5224.3M
Float 223.55M
% Held by Insiders 10.31%
% Held by Institutions 196.77%
Shares Short (Jul 31, 2019) 43.08M
Short Ratio (Jul 31, 2019) 41.55
Short % of Float (Jul 31, 2019) 41.63%
Short % of Shares Outstanding (Jul 31, 2019) 41.38%
Shares Short (prior month Jun 28, 2019) 43.19M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/2
Last Split Date 3May 23, 2011

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 29.64%
Operating Margin (ttm)42.09%

Management Effectiveness

Return on Assets (ttm)8.44%
Return on Equity (ttm)14.09%

Income Statement

Revenue (ttm)4.5B
Revenue Per Share (ttm)20.12
Quarterly Revenue Growth (yoy)15.10%
Gross Profit (ttm)3.76B
EBITDA 2.27B
Net Income Avi to Common (ttm)1.33B
Diluted EPS (ttm)5.90
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.1B
Total Cash Per Share (mrq)9.34
Total Debt (mrq)2.89B
Total Debt/Equity (mrq)28.48
Current Ratio (mrq)4.04
Book Value Per Share (mrq)45.33

Cash Flow Statement

Operating Cash Flow (ttm)1.44B
Levered Free Cash Flow (ttm)1.23B